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Acuros® XB commissioning for the Eclipse treatment planning 
system, and template development of specialized dose reports 
to analyze volumes defined within the patient’s structure set. In 
total, 90 lung, 18 spine, and two liver SBRT patients were treated 
from January 2014 to January 2016 using Varian 2300ix model 
linacs operated in 6MV SRS-mode. EPID reconstructed doses for 
each fraction were compared to Eclipse TPS AAA and Acuros dose 
calculations. Low dose (20% isodose) and high dose (planning 
target volume, PTV) regions were analyzed using gamma (3%/3 
mm). “Marginal” (< 90%) and “Suboptimal” (< 88%) pass rates 
were chosen based on the AAPM TG119 report. CBCTs, EPIDs, and 
linac output were investigated for all suboptimal fractions. 
Results: Improvements up to 8% in PTV γ-pass rates were 
observed when frame averaging was optimized. Furthermore, 
average γ-pass rates in the PTV improved from 89 ± 7% (AAA) to 
92 ± 5% (Acuros) for 32 lung patients, 71±15% (AAA) to 89±9% 
(Acuros) for nine spine patients, 90±3% (AAA) to 94 ± 1% (Acuros) 
for one liver patient. This was expected as Acuros is more 
accurate than AAA in calculating dose within complex 
heterogeneous media. Reasons for suboptimal fractions were 
identified as: 1) changes in patient anatomy with weight loss or 
gain, rotations, or shifts, or 2) changes in linac output, or errors 
in EPID image acquisition. Specific suboptimal cases will be 
presented to illustrate the utility of this in vivo dosimetry 
technique. 
Conclusions: In our study, γ-pass rates were higher using 
Acuros® XB for comparison and appeared to provide the most 
benefit in spine SBRT cases. With an increasing trend towards 
highly complex and high dose radiotherapy, in vivo dosimetry 
provides treatment verification of planned dose distributions. 
Furthermore, EPID in vivo dosimetry provides key information to 
permit adaptive radiotherapy approaches, potentially improving 
patient outcomes through more accurate dose delivery. Our 
results also highlight that complex treatments can be sensitive 
to changes in linac output and differences in patient orientation 
at the time of treatment with respect to the planning CT. 
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Purpose: Many individuals who use tobacco will continue to 
smoke after a cancer diagnosis and throughout treatment; 
however, the extant literature shows that many cancer patients 
are highly motivated to quit at this time. Continued smoking in 
cancer patients undergoing various treatments results in 
decreased treatment efficacy, potentially increased toxicity, 
reduced survival and increased risk of recurrence/second 
malignancy. This study aims to better understand cancer patient 
preferences for learning about smoking cessation.  
Methods and Materials: All new patients seen at Princess 
Margaret Cancer Centre between January 1, 2014 and June 30, 
2015 were asked to complete the Combined Tobacco History 
Survey as part of standard new patient assessments. Details 
collected from this survey include smoking status, second-hand 
smoke exposure, years smoked, family support and cessation 
preferences in terms of education modality. Demographic and 
tumour details were retrospectively collected from electronic 
patient records. The proportion of patients that were interested 
in each educational modality were calculated and difference by 
age and sex reported. Factors associated with smoking cessation 
educational preferences in univariate analyses were investigated 
further using multivariable regression analyses.  
Results: 9110 patients completed the survey. Among these there 
were 1691 smokers (17%). Forty-three percent were female and 
the median age was 57 years (range 18-95 years). Median years 
smoked was 30 years (range 0.5-80 years). Smokers included in 
this analysis were being treated predominantly for head and 
neck, gastrointestinal, genitourinary, gynecological and lung 
cancers. Of 1691 smokers, 1238 (73%) were willing to consider 
quitting and 953 (56%) reported a readiness to quit next month. 
Patients were most interested in getting smoking cessation 
education from pamphlets (45%) followed by telephone support 
(39%), speaking with a healthcare professional (29%), website 
(15%), support group (11%) and speaking with successful former 
smokers (9%). According to age tertiles, younger patients (≤ 45 
years) preferred receiving smoking cessation education over the 
telephone (50%; p < 0.001), while older patients (46-65 years and 
> 65 years) preferred smoking education to be provided in 
pamphlets (43% and 51% respectively; p = 0.07). In multivariable 
analyses, older patients were more likely to prefer pamphlets 
than younger patients OR 1.11 (95% CI: 1.01-1.23; p = 0.03). Sex 
and cancer site were not predictive of preference of education 
modality.  
Conclusions: Among cancer patients, older patients preferred to 
receive smoking cessation education through pamphlets and 
younger patients preferred to learn about smoking cessation over 
telephone. This highlights the importance of developing a 
tailored approach to smoking cessation for different cancer 
patient populations. These data provide an evidence base for 
future program development in cancer education. 
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Purpose: Sexual dysfunction in people with cancer is a 
significant problem. This guideline aimed to address the 
following question: “What is the effectiveness of pharmacologic 
interventions, psychosocial counselling or devices to manage 
sexual problems after cancer treatment?” 
Methods and Materials: This guideline was created with the 
support of the Program in Evidence-Based Care. We searched for 
existing systematic reviews, guidelines and relevant primary 
literature from 2003-2015. Men and women were evaluated 
separately. No restrictions were made on cancer type or study 
design. When first approaching the guideline the working group 
chose to focus on sexual disorders commonly known to arise in 
people with cancer. These included decreased desire, arousal 
disorders, pain (in women) and erectile dysfunction (in men). 
Only studies that evaluated the impact of an intervention on a 
sexual function outcome were included. 
Results: The panel made one overarching recommendation that 
there be a discussion with the patient, initiated by a member of 
the health care team, regarding sexual health and dysfunction 
resulting from the cancer or its treatment. The Expert Panel felt 
that this is vital since the additional recommendations cannot be 
used unless someone has taken the initiative to ask. There were 
numerous limitations of the existing literature. However, we 
made additional recommendations on 11 outcomes: six for 
women (sexual response, body image, intimacy/relationships, 
overall sexual function/satisfaction, vasomotor symptoms, 
genital symptoms) and five for men (sexual response, genital 
changes, intimacy/relationships, overall sexual 
function/satisfaction, vasomotor symptoms). There is a role for 
medication or devices in particular circumstances. Psychosocial 
counselling however had the largest evidentiary base for most of 
the outcomes. 
Conclusions: To our knowledge this is the first evidence based 
guideline to comprehensively evaluate interventions to improve 
sexual problems in people with cancer. The guideline will be a 
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valuable resource to support practitioners and clinics in 
addressing this important aspect of being human. 
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Purpose: A recently published practice-changing multicentre 
randomized study demonstrated no difference in overall survival 
(OS) and progression-free survival (PFS) between a short RT 
(arm1: 25 Gy in five fractions) and standard RT (arm 2: 40 Gy in 
15 fractions) in elderly and/or frail patients with glioblastoma 
multiforme (GBM). The purpose was to compare study arms for 
health-related quality of life (HR-QoL). 
Methods and Materials: EORTC core questionnaire QLQ-C30 and 
the brain module QLQ-BN20 were used to assess HR-QoL at 
baseline prior to RT, four weeks after RT completion and every 
three months thereafter until the disease progression. QoL 
scores over time were examined using generalized estimating 
equation adjusting for the treatment arms.  
Results: Of 98 randomized patients, 96 were eligible for QoL 
analysis. There was no difference in global QoL/main function 
scales/symptoms (except for insomnia) between arms. 
Improvement of global QoL, social and physical function, fatigue 
and insomnia were observed when comparing baseline to four 
months post-treatment, but only significant for insomnia, 
favouring arm 2. Difference of ≥ 10 points from baseline to four 
months was demonstrated for social function and insomnia (arm 
1), physical function (both arms) and fatigue (arm 2). Global QoL 
at baseline was significantly worse for arm 1, but statistically 
insignificant at one month and four months post-radiotherapy. 
Conclusions: There was overall no difference in HR-QoL between 
the two arms. A trend toward significant difference was seen in 
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Purpose: Cancer staging, which consists in objectifying the 
extent of cancer spread, is essential before the initiation of 
therapy. Staging is often incorrectly performed, with a sizeable 
portion of patients receiving unnecessary staging tests, which are 
costly. This study seeks to quantify the cost of such unnecessary 
tests in patients with early-stage breast cancer in the province 
of Québec, Canada. 
Methods and Materials: All patients diagnosed with breast 
cancer between 2012 and 2014 and listed in the tumour registry 
of the McGill University Health Centre, were included in this 
retrospective study. For each patient with early-stage breast 
cancer, the type and number of unnecessary staging tests, as per 
national guideline definitions, was extracted from the medical 
chart. The cost of each test, from a single payer point of view, 
was obtained from the Quebec government manuals of payment 
to physicians and departments. The total cost of unnecessary 
tests for staging of early-stage breast cancer was derived. 
Finally, an extrapolation was done to estimate the total cost for 
the whole province of Québec per year, given the number of 
diagnoses of breast cancer in that province. 
Results: 1845 patients were listed in the tumour registry of the 
MUHC, 1116 of which were diagnosed with early-stage breast 
cancer. 82.5% of patients underwent at least one inappropriate 
staging test, with an average of 2.35 inappropriate tests were 
performed per patient. Less than 1% of these tests detected 
metastatic disease. The average theoretical cost of 
inappropriate staging tests per patient was $235.84, $251.83 and 
$217.34 for 2012, 2013, and 2014 respectively, with an average 
total cost to the government of Québec of $830,659.61 per year, 
and a 10-year cost of $8,306,596.18. 
Conclusions: The majority of patients with early-stage breast 
cancer undergo unnecessary staging tests. In a social system with 




GLOBAL ACCESS TO RADIOTHERAPY FOR CERVICAL CANCER: THE 
COST OF INACTION  
Danielle Rodin1, Timothy P. Hanna2, Emily Burger3, Eduardo 
Zubizarreta4, Mei Ling Yap5, Michael Barton5, Rifat Atun3, Felicia 
Knaul6, Jacob Van Dyk7, Yolande Lievens8, Mary Gospodarowicz9, 
David Jaffray9, Michael Milosevic9 
1University of Toronto, Toronto, ON 
2Cancer Research Institute, Queen’s University, Kingston, ON 
3Harvard T.H. Chan School of Public Health, Boston, MA 
4International Atomic Energy Agency, Vienna, Austria 
5University of South Wales, Liverpool, Australia 
6University of Miami, Miami, FL 
7University of Western Ontario, London, ON 
8Ghent University Hospital, Ghent, Belgium 
9Princess Margaret Cancer Centre, Toronto, ON 
 
Purpose: Radiotherapy (RT) is a highly effective and curative 
treatment for patients with invasive cervical cancer, and is the 
standard of care for locally advanced disease. Although RT can 
be successfully delivered in developing countries, major gaps in 
access have resulted in substantial preventable morbidity and 
mortality, where nearly 90% of cervical cancer deaths occur. 
These gaps are multifactorial, but assumptions about excessive 
cost of RT in these regions preclude effective implementation. 
Using methodology developed for the Global Task Force on 
Radiotherapy for Cancer Control (GTFRCC), we examined the 
validity of these assumptions for the treatment of cervical 
cancer with external beam radiation (EBRT) and brachytherapy 
(BT) in upper middle-income income (UMIC), lower middle-
income (LMIC) and low-income countries (LIC). 
Methods and Materials: Based on the GTFRCC evidence-based 
estimation approach, we assumed that 71% of cervical cancer 
patients would require RT, with a mean of 21 EBRT and three 
HDR BT fractions per course, resulting in a 20% overall survival 
benefit. We developed a decision-analytic Markov model to 
assess three RT capacity scenarios from 2015 to 2035: 1) no 
increase in capacity; 2) linear scale-up from baseline coverage 
in 2015 to universal accessibility by 2035; and 3) immediate full 
availability. Model outcomes included total life years (LYs) and 
economic productivity (US Dollar). Costs, based on the GTFRCC 
efficiency model, and benefits were discounted by 3% annually 
over a lifetime horizon. 
Results: If no action is taken to shift current RT capacity to 
universal accessibility, we project a loss of up to 21.4 million (M) 
